| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 67 | 2024 | 215 | 14.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 107 | 2016 | 179 | 10.830 |
Why?
|
| Rhinitis | 62 | 2024 | 179 | 10.810 |
Why?
|
| Nasal Polyps | 22 | 2024 | 61 | 7.190 |
Why?
|
| Rhinitis, Allergic, Perennial | 47 | 2014 | 81 | 5.730 |
Why?
|
| Nasal Mucosa | 94 | 2014 | 191 | 5.720 |
Why?
|
| Nasal Provocation Tests | 85 | 2013 | 129 | 4.900 |
Why?
|
| Allergens | 48 | 2016 | 183 | 3.710 |
Why?
|
| Hypersensitivity | 37 | 2021 | 158 | 3.580 |
Why?
|
| Anti-Allergic Agents | 17 | 2019 | 39 | 3.350 |
Why?
|
| Nose | 20 | 2013 | 94 | 3.020 |
Why?
|
| Histamine | 48 | 2013 | 126 | 2.650 |
Why?
|
| Humidity | 29 | 2008 | 92 | 2.570 |
Why?
|
| Nasal Cavity | 23 | 2013 | 91 | 2.420 |
Why?
|
| Androstadienes | 11 | 2013 | 72 | 2.060 |
Why?
|
| Pneumococcal Infections | 11 | 2008 | 47 | 2.060 |
Why?
|
| Chronic Disease | 40 | 2024 | 950 | 1.980 |
Why?
|
| Rhinitis, Allergic | 11 | 2024 | 45 | 1.940 |
Why?
|
| Histamine H1 Antagonists | 19 | 2003 | 40 | 1.920 |
Why?
|
| Administration, Intranasal | 40 | 2020 | 137 | 1.870 |
Why?
|
| Air | 19 | 2008 | 62 | 1.860 |
Why?
|
| Immunoglobulin E | 24 | 2020 | 145 | 1.760 |
Why?
|
| Histamine Release | 37 | 2008 | 53 | 1.760 |
Why?
|
| Anti-Inflammatory Agents | 17 | 2019 | 345 | 1.750 |
Why?
|
| Eosinophils | 26 | 2020 | 194 | 1.630 |
Why?
|
| Double-Blind Method | 62 | 2020 | 1719 | 1.630 |
Why?
|
| Humans | 308 | 2024 | 89357 | 1.570 |
Why?
|
| Endoscopy | 10 | 2020 | 350 | 1.380 |
Why?
|
| Maxillary Sinusitis | 5 | 2015 | 16 | 1.370 |
Why?
|
| Loratadine | 12 | 2013 | 21 | 1.340 |
Why?
|
| Cross-Over Studies | 26 | 2016 | 389 | 1.310 |
Why?
|
| Asthma | 19 | 2021 | 978 | 1.280 |
Why?
|
| Biological Products | 4 | 2021 | 155 | 1.280 |
Why?
|
| Paranasal Sinuses | 16 | 2013 | 60 | 1.260 |
Why?
|
| Conjunctivitis, Allergic | 4 | 2009 | 10 | 1.240 |
Why?
|
| Adult | 145 | 2022 | 26607 | 1.210 |
Why?
|
| Cold Temperature | 18 | 2007 | 160 | 1.170 |
Why?
|
| Pollen | 28 | 2013 | 82 | 1.150 |
Why?
|
| Antigens | 25 | 2001 | 229 | 1.130 |
Why?
|
| Hot Temperature | 8 | 2008 | 208 | 1.120 |
Why?
|
| Male | 137 | 2019 | 42411 | 1.100 |
Why?
|
| Eye | 4 | 2013 | 111 | 1.090 |
Why?
|
| Female | 142 | 2022 | 46202 | 1.090 |
Why?
|
| Streptococcus pneumoniae | 10 | 2006 | 49 | 1.080 |
Why?
|
| Sneezing | 25 | 2011 | 36 | 1.020 |
Why?
|
| Terfenadine | 14 | 2024 | 23 | 1.020 |
Why?
|
| Maxillary Sinus | 6 | 2013 | 26 | 1.010 |
Why?
|
| Otolaryngology | 4 | 2014 | 55 | 0.990 |
Why?
|
| Peptide Hydrolases | 40 | 1997 | 101 | 0.950 |
Why?
|
| Glucocorticoids | 11 | 2014 | 358 | 0.940 |
Why?
|
| Nasal Lavage Fluid | 14 | 2012 | 26 | 0.880 |
Why?
|
| Eosinophilia | 4 | 2017 | 84 | 0.880 |
Why?
|
| Budesonide | 5 | 2014 | 46 | 0.850 |
Why?
|
| Pregnadienediols | 4 | 2022 | 13 | 0.830 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 969 | 0.820 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.800 |
Why?
|
| Reflex | 9 | 2013 | 80 | 0.790 |
Why?
|
| Quinolines | 6 | 2010 | 91 | 0.780 |
Why?
|
| Kinins | 28 | 1997 | 31 | 0.780 |
Why?
|
| Dibenzoxepins | 2 | 2013 | 5 | 0.770 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 7 | 2024 | 15 | 0.720 |
Why?
|
| Beclomethasone | 8 | 1998 | 16 | 0.720 |
Why?
|
| Quality of Life | 20 | 2023 | 1668 | 0.700 |
Why?
|
| Antibodies, Anti-Idiotypic | 7 | 2017 | 44 | 0.690 |
Why?
|
| Mast Cells | 25 | 2002 | 94 | 0.690 |
Why?
|
| Epinephrine | 1 | 2020 | 88 | 0.690 |
Why?
|
| Nasal Obstruction | 6 | 2011 | 21 | 0.690 |
Why?
|
| Middle Aged | 84 | 2019 | 25974 | 0.690 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2022 | 266 | 0.660 |
Why?
|
| Tonsillectomy | 3 | 2016 | 30 | 0.660 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.630 |
Why?
|
| Mucociliary Clearance | 3 | 2011 | 7 | 0.630 |
Why?
|
| Biological Therapy | 1 | 2018 | 47 | 0.620 |
Why?
|
| Temperature | 7 | 2007 | 404 | 0.610 |
Why?
|
| Methacholine Chloride | 12 | 2008 | 65 | 0.610 |
Why?
|
| Ipratropium | 6 | 2003 | 18 | 0.610 |
Why?
|
| Water | 4 | 2011 | 283 | 0.610 |
Why?
|
| Inhalation | 3 | 2010 | 31 | 0.600 |
Why?
|
| Adenoidectomy | 3 | 2016 | 23 | 0.600 |
Why?
|
| Anesthesia, Inhalation | 3 | 2013 | 36 | 0.580 |
Why?
|
| Nasal Sprays | 4 | 2016 | 9 | 0.580 |
Why?
|
| Adolescent | 53 | 2016 | 9263 | 0.570 |
Why?
|
| Immunologic Factors | 1 | 2018 | 171 | 0.570 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1799 | 0.560 |
Why?
|
| Ambrosia | 7 | 2012 | 14 | 0.560 |
Why?
|
| Methyl Ethers | 2 | 2013 | 33 | 0.560 |
Why?
|
| Anesthesia, Intravenous | 2 | 2013 | 35 | 0.560 |
Why?
|
| Oxymetazoline | 6 | 2011 | 10 | 0.550 |
Why?
|
| Ovalbumin | 6 | 2006 | 109 | 0.550 |
Why?
|
| Nasal Decongestants | 2 | 2011 | 10 | 0.550 |
Why?
|
| Forehead | 1 | 2016 | 15 | 0.540 |
Why?
|
| Acetates | 5 | 2010 | 65 | 0.540 |
Why?
|
| Skull Neoplasms | 1 | 2016 | 30 | 0.540 |
Why?
|
| Pain, Postoperative | 3 | 2016 | 252 | 0.540 |
Why?
|
| Retinoblastoma | 1 | 2016 | 29 | 0.540 |
Why?
|
| Propofol | 2 | 2013 | 92 | 0.540 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 115 | 0.540 |
Why?
|
| Respiratory Mechanics | 3 | 2011 | 102 | 0.530 |
Why?
|
| Atropine | 7 | 1996 | 60 | 0.530 |
Why?
|
| Leukotriene Antagonists | 6 | 2010 | 25 | 0.530 |
Why?
|
| Cellulose | 1 | 2016 | 56 | 0.520 |
Why?
|
| Mycoses | 1 | 2016 | 46 | 0.520 |
Why?
|
| Cytokines | 4 | 2018 | 803 | 0.520 |
Why?
|
| Analgesics | 1 | 2016 | 119 | 0.510 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2016 | 2661 | 0.510 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.500 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 25 | 0.500 |
Why?
|
| Aspergillosis | 1 | 2015 | 41 | 0.490 |
Why?
|
| Osteosarcoma | 1 | 2016 | 161 | 0.490 |
Why?
|
| Hypersensitivity, Immediate | 4 | 2006 | 63 | 0.480 |
Why?
|
| Neutrophils | 10 | 2001 | 308 | 0.480 |
Why?
|
| Cancer Survivors | 1 | 2016 | 95 | 0.480 |
Why?
|
| Common Cold | 6 | 2021 | 13 | 0.470 |
Why?
|
| Body Temperature | 3 | 2005 | 125 | 0.470 |
Why?
|
| Personnel Selection | 1 | 2014 | 60 | 0.460 |
Why?
|
| Clinical Trials as Topic | 13 | 2020 | 1150 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 260 | 0.450 |
Why?
|
| Acute Disease | 13 | 2016 | 841 | 0.450 |
Why?
|
| Ribonucleases | 3 | 2001 | 94 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1412 | 0.450 |
Why?
|
| Nasal Septum | 5 | 2014 | 28 | 0.430 |
Why?
|
| Treatment Outcome | 22 | 2022 | 8241 | 0.410 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 393 | 0.410 |
Why?
|
| Internship and Residency | 2 | 2014 | 1045 | 0.410 |
Why?
|
| Patient Selection | 2 | 2018 | 684 | 0.400 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2366 | 0.400 |
Why?
|
| Bronchial Provocation Tests | 8 | 2008 | 25 | 0.400 |
Why?
|
| Basophils | 15 | 1994 | 26 | 0.400 |
Why?
|
| Skin Temperature | 2 | 2003 | 15 | 0.390 |
Why?
|
| Prostaglandin D2 | 20 | 1996 | 28 | 0.390 |
Why?
|
| Albumins | 15 | 2008 | 129 | 0.390 |
Why?
|
| Desensitization, Immunologic | 7 | 1995 | 37 | 0.390 |
Why?
|
| Prednisone | 8 | 2014 | 259 | 0.390 |
Why?
|
| Ioxaglic Acid | 1 | 2011 | 7 | 0.380 |
Why?
|
| Th2 Cells | 4 | 2020 | 147 | 0.370 |
Why?
|
| Leukocyte Count | 11 | 2012 | 223 | 0.370 |
Why?
|
| Cetirizine | 8 | 2013 | 12 | 0.360 |
Why?
|
| Mice, Inbred BALB C | 8 | 2006 | 1088 | 0.360 |
Why?
|
| Comorbidity | 6 | 2023 | 949 | 0.360 |
Why?
|
| Mice | 18 | 2008 | 11761 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2013 | 1942 | 0.360 |
Why?
|
| Eye Diseases | 2 | 2008 | 58 | 0.360 |
Why?
|
| Maxillary Diseases | 1 | 2010 | 3 | 0.350 |
Why?
|
| Tooth Extraction | 1 | 2010 | 10 | 0.350 |
Why?
|
| Pulmonary Ventilation | 2 | 2011 | 33 | 0.340 |
Why?
|
| Bradykinin | 6 | 1995 | 46 | 0.340 |
Why?
|
| Vitamin D | 2 | 2010 | 269 | 0.340 |
Why?
|
| Olfactory Mucosa | 2 | 2010 | 33 | 0.340 |
Why?
|
| Reflex, Abnormal | 1 | 2009 | 6 | 0.340 |
Why?
|
| Biomarkers | 10 | 2019 | 1767 | 0.330 |
Why?
|
| Conjunctiva | 1 | 2009 | 19 | 0.330 |
Why?
|
| Foreign Bodies | 1 | 2010 | 66 | 0.330 |
Why?
|
| Cysts | 1 | 2010 | 106 | 0.320 |
Why?
|
| Job Application | 1 | 2008 | 8 | 0.320 |
Why?
|
| Analysis of Variance | 10 | 2006 | 899 | 0.320 |
Why?
|
| Animals | 25 | 2016 | 27371 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 9 | 2008 | 3218 | 0.310 |
Why?
|
| Flow Cytometry | 7 | 2014 | 691 | 0.310 |
Why?
|
| Calcinosis | 1 | 2010 | 230 | 0.310 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.310 |
Why?
|
| Urban Health | 1 | 2008 | 56 | 0.310 |
Why?
|
| Time Factors | 24 | 2013 | 5338 | 0.310 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 31 | 0.310 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 29 | 0.310 |
Why?
|
| Foot | 3 | 2003 | 52 | 0.310 |
Why?
|
| Plant Proteins | 5 | 2013 | 134 | 0.300 |
Why?
|
| Inflammation | 14 | 2010 | 972 | 0.300 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 52 | 0.300 |
Why?
|
| Surveys and Questionnaires | 12 | 2012 | 2624 | 0.300 |
Why?
|
| Mometasone Furoate | 6 | 2022 | 18 | 0.300 |
Why?
|
| Young Adult | 10 | 2016 | 6312 | 0.300 |
Why?
|
| Algorithms | 2 | 2015 | 1877 | 0.290 |
Why?
|
| Placebos | 9 | 2019 | 214 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 242 | 0.290 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 91 | 0.290 |
Why?
|
| Immunotherapy | 9 | 1995 | 682 | 0.290 |
Why?
|
| Biopsy | 5 | 2016 | 1184 | 0.290 |
Why?
|
| Drug Therapy, Combination | 6 | 2013 | 784 | 0.280 |
Why?
|
| Colony Count, Microbial | 4 | 2008 | 46 | 0.280 |
Why?
|
| Respirovirus Infections | 1 | 2006 | 12 | 0.280 |
Why?
|
| Steroids | 3 | 2011 | 174 | 0.280 |
Why?
|
| Capillary Permeability | 8 | 2013 | 130 | 0.280 |
Why?
|
| Environmental Pollutants | 1 | 2007 | 51 | 0.270 |
Why?
|
| Aza Compounds | 1 | 2006 | 8 | 0.270 |
Why?
|
| Azithromycin | 1 | 2006 | 13 | 0.270 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 24 | 0.270 |
Why?
|
| Dexamethasone | 1 | 2008 | 344 | 0.270 |
Why?
|
| Atmosphere Exposure Chambers | 3 | 2001 | 7 | 0.270 |
Why?
|
| Sodium Chloride | 1 | 2006 | 88 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2007 | 231 | 0.260 |
Why?
|
| Child | 22 | 2016 | 7174 | 0.250 |
Why?
|
| Cystic Fibrosis | 4 | 2000 | 115 | 0.250 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 91 | 0.250 |
Why?
|
| Phthalazines | 4 | 2008 | 45 | 0.250 |
Why?
|
| Aged | 20 | 2016 | 19165 | 0.240 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 461 | 0.240 |
Why?
|
| T-Lymphocytes | 4 | 2006 | 1224 | 0.240 |
Why?
|
| Inflammation Mediators | 4 | 2019 | 153 | 0.240 |
Why?
|
| Airway Resistance | 10 | 1999 | 70 | 0.230 |
Why?
|
| Ephedrine | 3 | 2006 | 6 | 0.230 |
Why?
|
| Nose Neoplasms | 2 | 2000 | 31 | 0.230 |
Why?
|
| Hydroxyzine | 4 | 1991 | 7 | 0.230 |
Why?
|
| Th1 Cells | 4 | 2006 | 166 | 0.220 |
Why?
|
| Prostaglandins D | 14 | 1989 | 15 | 0.220 |
Why?
|
| Respiratory System | 3 | 2011 | 116 | 0.220 |
Why?
|
| Maxillary Neoplasms | 1 | 2003 | 6 | 0.220 |
Why?
|
| Parasympathetic Nervous System | 4 | 2001 | 36 | 0.220 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 433 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 5 | 2015 | 1047 | 0.220 |
Why?
|
| Carcinoma, Verrucous | 1 | 2003 | 7 | 0.220 |
Why?
|
| Severity of Illness Index | 6 | 2012 | 1840 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 788 | 0.210 |
Why?
|
| Leukotrienes | 3 | 1991 | 20 | 0.210 |
Why?
|
| Serum Albumin | 9 | 2002 | 127 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 32 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2004 | 184 | 0.210 |
Why?
|
| Poaceae | 5 | 2011 | 19 | 0.210 |
Why?
|
| Administration, Oral | 7 | 2006 | 682 | 0.200 |
Why?
|
| Respiration Disorders | 2 | 2020 | 41 | 0.200 |
Why?
|
| Therapeutic Irrigation | 11 | 2002 | 61 | 0.200 |
Why?
|
| United States | 7 | 2021 | 6989 | 0.200 |
Why?
|
| Research | 2 | 2001 | 252 | 0.200 |
Why?
|
| Respiratory Hypersensitivity | 6 | 1999 | 41 | 0.200 |
Why?
|
| Supine Position | 1 | 2001 | 30 | 0.200 |
Why?
|
| Middle Ear Ventilation | 2 | 1992 | 4 | 0.200 |
Why?
|
| Fluticasone | 6 | 2010 | 30 | 0.200 |
Why?
|
| Consensus | 3 | 2021 | 356 | 0.200 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 306 | 0.200 |
Why?
|
| Administration, Topical | 7 | 2008 | 96 | 0.190 |
Why?
|
| Prospective Studies | 11 | 2013 | 4289 | 0.190 |
Why?
|
| Olopatadine Hydrochloride | 2 | 2013 | 6 | 0.190 |
Why?
|
| Serine Endopeptidases | 3 | 2002 | 146 | 0.190 |
Why?
|
| Receptors, Muscarinic | 1 | 2001 | 48 | 0.190 |
Why?
|
| Disease Progression | 3 | 2015 | 1489 | 0.190 |
Why?
|
| Cyproheptadine | 6 | 1993 | 10 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2021 | 102 | 0.180 |
Why?
|
| Premedication | 4 | 1994 | 58 | 0.180 |
Why?
|
| Sublingual Immunotherapy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 56 | 0.180 |
Why?
|
| Cholinergic Antagonists | 2 | 2003 | 27 | 0.180 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2000 | 18 | 0.180 |
Why?
|
| Reaction Time | 1 | 2001 | 310 | 0.180 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.180 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 66 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 306 | 0.180 |
Why?
|
| Hemostasis | 1 | 2020 | 21 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2000 | 56 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 49 | 0.170 |
Why?
|
| Blood Proteins | 3 | 2001 | 146 | 0.170 |
Why?
|
| Microbiota | 2 | 2016 | 402 | 0.170 |
Why?
|
| Interleukin-4 | 3 | 2017 | 130 | 0.170 |
Why?
|
| Phenotype | 4 | 2016 | 2440 | 0.170 |
Why?
|
| Interleukin-13 | 2 | 2017 | 38 | 0.170 |
Why?
|
| Turbinates | 4 | 2011 | 11 | 0.170 |
Why?
|
| Pharmacies | 1 | 2019 | 10 | 0.170 |
Why?
|
| Exophthalmos | 1 | 1999 | 5 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 2 | 1998 | 45 | 0.170 |
Why?
|
| Diagnosis, Differential | 6 | 2013 | 1597 | 0.170 |
Why?
|
| Orbital Neoplasms | 1 | 1999 | 17 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2019 | 37 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 120 | 0.160 |
Why?
|
| Telemedicine | 2 | 2019 | 188 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2018 | 5 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1862 | 0.160 |
Why?
|
| Allergy and Immunology | 2 | 2011 | 13 | 0.160 |
Why?
|
| Random Allocation | 9 | 2001 | 327 | 0.160 |
Why?
|
| Diphenhydramine | 3 | 1993 | 17 | 0.160 |
Why?
|
| Triamcinolone Acetonide | 2 | 1998 | 8 | 0.160 |
Why?
|
| Airway Obstruction | 2 | 2011 | 111 | 0.160 |
Why?
|
| Aerosols | 5 | 2011 | 45 | 0.150 |
Why?
|
| Community Health Services | 1 | 2019 | 82 | 0.150 |
Why?
|
| SRS-A | 14 | 1989 | 27 | 0.150 |
Why?
|
| Pregnancy | 2 | 2022 | 3018 | 0.150 |
Why?
|
| Respiratory Mucosa | 2 | 2013 | 88 | 0.150 |
Why?
|
| Antibody Formation | 4 | 1997 | 171 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 1714 | 0.150 |
Why?
|
| Smoking | 2 | 2016 | 621 | 0.140 |
Why?
|
| Carcinoma | 1 | 2000 | 443 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Platelet Activating Factor | 3 | 1994 | 53 | 0.140 |
Why?
|
| Respiratory Therapy | 1 | 1997 | 14 | 0.140 |
Why?
|
| Codeine | 1 | 2016 | 12 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 341 | 0.140 |
Why?
|
| Theophylline | 3 | 1987 | 33 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 1719 | 0.140 |
Why?
|
| Omalizumab | 2 | 2021 | 8 | 0.140 |
Why?
|
| Cyclopropanes | 5 | 2010 | 25 | 0.140 |
Why?
|
| Hypertelorism | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cilia | 1 | 2016 | 29 | 0.140 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 47 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2002 | 1063 | 0.140 |
Why?
|
| CD8 Antigens | 2 | 2006 | 82 | 0.140 |
Why?
|
| Respiration | 3 | 2000 | 267 | 0.130 |
Why?
|
| CD4 Antigens | 2 | 2006 | 83 | 0.130 |
Why?
|
| Hypersensitivity, Delayed | 3 | 1990 | 25 | 0.130 |
Why?
|
| Sulfides | 5 | 2010 | 68 | 0.130 |
Why?
|
| Drug Utilization | 1 | 2016 | 66 | 0.130 |
Why?
|
| CD11b Antigen | 2 | 2006 | 36 | 0.130 |
Why?
|
| Probability | 2 | 2008 | 353 | 0.130 |
Why?
|
| Growth Disorders | 1 | 1996 | 63 | 0.130 |
Why?
|
| Benzhydryl Compounds | 3 | 1990 | 44 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 461 | 0.130 |
Why?
|
| Muscarinic Antagonists | 1 | 1996 | 58 | 0.130 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 249 | 0.130 |
Why?
|
| Facial Pain | 1 | 2015 | 11 | 0.130 |
Why?
|
| Reference Values | 4 | 2013 | 661 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Choanal Atresia | 1 | 1994 | 2 | 0.120 |
Why?
|
| Vision Disorders | 1 | 2015 | 75 | 0.120 |
Why?
|
| Ketotifen | 2 | 1993 | 3 | 0.120 |
Why?
|
| Child, Preschool | 10 | 2010 | 3731 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 330 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 4 | 1997 | 167 | 0.120 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 41 | 0.120 |
Why?
|
| Nasal Septal Perforation | 1 | 2014 | 3 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2015 | 120 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 122 | 0.120 |
Why?
|
| Seasons | 5 | 1997 | 237 | 0.120 |
Why?
|
| Eosinophil Granule Proteins | 3 | 2001 | 20 | 0.120 |
Why?
|
| Mucous Membrane | 3 | 2001 | 83 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 773 | 0.120 |
Why?
|
| Skin Tests | 9 | 2010 | 44 | 0.120 |
Why?
|
| Prostaglandins | 3 | 1996 | 42 | 0.110 |
Why?
|
| Nasopharynx | 3 | 2021 | 50 | 0.110 |
Why?
|
| Histamine H2 Antagonists | 1 | 1993 | 15 | 0.110 |
Why?
|
| Television | 1 | 2013 | 29 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2013 | 82 | 0.110 |
Why?
|
| Prevalence | 4 | 2012 | 1243 | 0.110 |
Why?
|
| Genome, Human | 2 | 2008 | 767 | 0.110 |
Why?
|
| Cynodon | 1 | 2013 | 2 | 0.110 |
Why?
|
| Endo-1,4-beta Xylanases | 1 | 2013 | 3 | 0.110 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cysteine Proteases | 1 | 2013 | 4 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2013 | 232 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2013 | 3666 | 0.110 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2006 | 67 | 0.110 |
Why?
|
| Leukocytes | 3 | 2001 | 204 | 0.110 |
Why?
|
| Environmental Health | 1 | 1992 | 8 | 0.100 |
Why?
|
| Immune System | 1 | 1993 | 97 | 0.100 |
Why?
|
| Immersion | 2 | 2003 | 21 | 0.100 |
Why?
|
| Immunoglobulin G | 6 | 1997 | 465 | 0.100 |
Why?
|
| Urticaria | 4 | 2024 | 14 | 0.100 |
Why?
|
| Antigens, Plant | 6 | 2011 | 14 | 0.100 |
Why?
|
| Anesthesia, Local | 2 | 1993 | 27 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 444 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2014 | 249 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 199 | 0.100 |
Why?
|
| Acetaminophen | 1 | 1992 | 56 | 0.100 |
Why?
|
| Antibody Specificity | 3 | 1997 | 130 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 8 | 2007 | 42 | 0.100 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1991 | 5 | 0.100 |
Why?
|
| Allergists | 2 | 2021 | 4 | 0.090 |
Why?
|
| Phenols | 1 | 1991 | 41 | 0.090 |
Why?
|
| Air Pollutants | 1 | 1992 | 92 | 0.090 |
Why?
|
| Trees | 1 | 2011 | 37 | 0.090 |
Why?
|
| Hypertonic Solutions | 1 | 1990 | 17 | 0.090 |
Why?
|
| Pulmonary Medicine | 1 | 2011 | 46 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 61 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 275 | 0.090 |
Why?
|
| Phenylbutyrates | 1 | 1990 | 9 | 0.090 |
Why?
|
| Lidocaine | 3 | 2003 | 65 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 595 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2011 | 202 | 0.090 |
Why?
|
| Cell Count | 4 | 1991 | 200 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2884 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 103 | 0.090 |
Why?
|
| Anesthesia, General | 1 | 1991 | 118 | 0.090 |
Why?
|
| Plant Extracts | 2 | 2008 | 245 | 0.090 |
Why?
|
| Forecasting | 1 | 2011 | 306 | 0.090 |
Why?
|
| Cell Movement | 5 | 1998 | 784 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1365 | 0.090 |
Why?
|
| Genetic Linkage | 2 | 2008 | 624 | 0.080 |
Why?
|
| Neurotoxins | 1 | 1989 | 49 | 0.080 |
Why?
|
| Nose Diseases | 1 | 2009 | 11 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 895 | 0.080 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 200 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 19 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2340 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2015 | 9057 | 0.080 |
Why?
|
| Epithelium | 3 | 1998 | 325 | 0.080 |
Why?
|
| Disease Management | 3 | 2019 | 329 | 0.080 |
Why?
|
| Recurrence | 4 | 1997 | 1144 | 0.080 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 40 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2002 | 233 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2013 | 689 | 0.080 |
Why?
|
| Tosylarginine Methyl Ester | 4 | 1994 | 5 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 79 | 0.080 |
Why?
|
| Osmolar Concentration | 5 | 1992 | 181 | 0.080 |
Why?
|
| Exudates and Transudates | 1 | 1988 | 14 | 0.080 |
Why?
|
| Tryptases | 3 | 2002 | 12 | 0.080 |
Why?
|
| Leukotriene B4 | 4 | 1996 | 14 | 0.080 |
Why?
|
| Pharyngitis | 1 | 1988 | 15 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1072 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 988 | 0.080 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 48 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 1998 | 56 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2012 | 466 | 0.080 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 192 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2003 | 198 | 0.070 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2008 | 77 | 0.070 |
Why?
|
| Arachidonic Acids | 2 | 1987 | 41 | 0.070 |
Why?
|
| Hydroxycorticosteroids | 1 | 2007 | 2 | 0.070 |
Why?
|
| Xerostomia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Adoptive Transfer | 2 | 2005 | 169 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.070 |
Why?
|
| Receptors, Histamine H1 | 2 | 2000 | 8 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 2758 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 224 | 0.070 |
Why?
|
| Siblings | 1 | 2007 | 111 | 0.070 |
Why?
|
| Olfaction Disorders | 1 | 2008 | 68 | 0.070 |
Why?
|
| Sheep | 1 | 2007 | 251 | 0.070 |
Why?
|
| Sendai virus | 1 | 2006 | 8 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2006 | 78 | 0.070 |
Why?
|
| Muscarinic Agonists | 2 | 1996 | 22 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2006 | 22 | 0.070 |
Why?
|
| Chicago | 1 | 2011 | 1427 | 0.070 |
Why?
|
| Mucus | 2 | 1987 | 19 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 33 | 0.070 |
Why?
|
| Environment | 1 | 2008 | 223 | 0.070 |
Why?
|
| Rhinovirus | 3 | 1990 | 25 | 0.070 |
Why?
|
| Glycolipids | 1 | 2005 | 29 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 639 | 0.060 |
Why?
|
| Headache | 1 | 2006 | 72 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2005 | 134 | 0.060 |
Why?
|
| Chymases | 2 | 1996 | 11 | 0.060 |
Why?
|
| Osteoma, Osteoid | 1 | 1985 | 8 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2005 | 30 | 0.060 |
Why?
|
| Gene Regulatory Networks | 1 | 2008 | 308 | 0.060 |
Why?
|
| Facial Paralysis | 1 | 1985 | 17 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 1998 | 38 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 371 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2008 | 537 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2006 | 2001 | 0.060 |
Why?
|
| Tachyphylaxis | 3 | 1994 | 14 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 6811 | 0.060 |
Why?
|
| Kinetics | 3 | 1999 | 1528 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2006 | 329 | 0.060 |
Why?
|
| Temporal Bone | 1 | 1985 | 67 | 0.060 |
Why?
|
| Phospholipases A | 2 | 1994 | 45 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2014 | 871 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2024 | 74 | 0.060 |
Why?
|
| Cell Separation | 3 | 2014 | 198 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2013 | 42 | 0.060 |
Why?
|
| Radioallergosorbent Test | 4 | 1993 | 8 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 2013 | 426 | 0.060 |
Why?
|
| Penicillins | 1 | 1983 | 20 | 0.050 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2013 | 25 | 0.050 |
Why?
|
| Kininogens | 4 | 1986 | 6 | 0.050 |
Why?
|
| Stem Cells | 1 | 2005 | 372 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 1983 | 37 | 0.050 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 96 | 0.050 |
Why?
|
| Prognosis | 3 | 2013 | 3783 | 0.050 |
Why?
|
| Lactoferrin | 3 | 1998 | 11 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 636 | 0.050 |
Why?
|
| Lymphocytes | 1 | 1985 | 471 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 76 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 1308 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 2 | 1994 | 56 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 445 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 1983 | 55 | 0.050 |
Why?
|
| Drug Liberation | 1 | 2022 | 16 | 0.050 |
Why?
|
| Capsaicin | 3 | 1999 | 45 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 1985 | 329 | 0.050 |
Why?
|
| Pedigree | 3 | 2008 | 970 | 0.050 |
Why?
|
| Ozone | 2 | 1992 | 8 | 0.050 |
Why?
|
| Neuropeptides | 2 | 1999 | 114 | 0.050 |
Why?
|
| Information Technology | 1 | 2021 | 4 | 0.050 |
Why?
|
| Tympanoplasty | 1 | 1981 | 13 | 0.050 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.050 |
Why?
|
| Mastoid | 1 | 1981 | 17 | 0.050 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2001 | 13 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2001 | 85 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 92 | 0.050 |
Why?
|
| Acoustics | 1 | 2001 | 51 | 0.050 |
Why?
|
| Glottis | 1 | 1980 | 11 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2002 | 333 | 0.050 |
Why?
|
| Atrophy | 1 | 2001 | 120 | 0.050 |
Why?
|
| Workload | 1 | 2001 | 129 | 0.050 |
Why?
|
| Triage | 1 | 2021 | 111 | 0.040 |
Why?
|
| World Health Organization | 2 | 2012 | 106 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 2015 | 0.040 |
Why?
|
| Masks | 1 | 2000 | 29 | 0.040 |
Why?
|
| Histamine Antagonists | 2 | 1991 | 13 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 163 | 0.040 |
Why?
|
| Aspirin | 4 | 1991 | 159 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 1980 | 89 | 0.040 |
Why?
|
| Immunization | 2 | 1998 | 160 | 0.040 |
Why?
|
| Otitis Media with Effusion | 2 | 1992 | 6 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2001 | 186 | 0.040 |
Why?
|
| Infant | 5 | 1994 | 3160 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 838 | 0.040 |
Why?
|
| Pharmacists | 1 | 2019 | 33 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 21 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2000 | 111 | 0.040 |
Why?
|
| Immunity, Cellular | 3 | 1991 | 178 | 0.040 |
Why?
|
| Professional Role | 1 | 2019 | 41 | 0.040 |
Why?
|
| Bacteria | 2 | 2014 | 478 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1992 | 138 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 66 | 0.040 |
Why?
|
| Administration, Inhalation | 2 | 1997 | 190 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 215 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 284 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 105 | 0.040 |
Why?
|
| Adenoma | 1 | 1980 | 246 | 0.040 |
Why?
|
| Immunologic Tests | 1 | 1997 | 6 | 0.040 |
Why?
|
| Fluocinolone Acetonide | 2 | 1988 | 8 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 120 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 140 | 0.040 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Clemastine | 1 | 1997 | 2 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.040 |
Why?
|
| Peroxidases | 1 | 1997 | 34 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Nasal Surgical Procedures | 1 | 2016 | 8 | 0.040 |
Why?
|
| Dinoprost | 1 | 1996 | 26 | 0.040 |
Why?
|
| Endothelium | 1 | 1997 | 58 | 0.040 |
Why?
|
| Albuterol | 1 | 1997 | 35 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 75 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 72 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 67 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 3 | 1991 | 26 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 1997 | 65 | 0.030 |
Why?
|
| Kallikreins | 2 | 1986 | 49 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 645 | 0.030 |
Why?
|
| Nerve Endings | 1 | 1996 | 16 | 0.030 |
Why?
|
| Sphenoid Sinus | 1 | 1995 | 7 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 48 | 0.030 |
Why?
|
| Lung | 6 | 2008 | 1263 | 0.030 |
Why?
|
| Web Browser | 1 | 2015 | 5 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 125 | 0.030 |
Why?
|
| Age Factors | 2 | 1998 | 1870 | 0.030 |
Why?
|
| Health Planning | 1 | 2015 | 17 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1996 | 287 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2015 | 49 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1076 | 0.030 |
Why?
|
| Mucocele | 1 | 1994 | 4 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 286 | 0.030 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1994 | 8 | 0.030 |
Why?
|
| Fascia Lata | 1 | 2014 | 7 | 0.030 |
Why?
|
| Acute-Phase Reaction | 1 | 1994 | 16 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 48 | 0.030 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 68 | 0.030 |
Why?
|
| Mannitol | 2 | 1992 | 50 | 0.030 |
Why?
|
| Cartilage | 1 | 2014 | 116 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 2285 | 0.030 |
Why?
|
| Frontal Sinusitis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Sphenoid Sinusitis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Ethmoid Sinusitis | 1 | 1993 | 4 | 0.030 |
Why?
|
| Cephalometry | 1 | 1993 | 50 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1987 | 315 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 185 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2004 | 160 | 0.030 |
Why?
|
| Patient Care | 2 | 2004 | 102 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1995 | 232 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 41 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 77 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 261 | 0.030 |
Why?
|
| Paper | 1 | 1992 | 12 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 171 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 281 | 0.030 |
Why?
|
| Linear Models | 1 | 1994 | 421 | 0.030 |
Why?
|
| Filtration | 1 | 1992 | 25 | 0.030 |
Why?
|
| Americas | 1 | 2012 | 19 | 0.030 |
Why?
|
| Esterases | 1 | 1992 | 13 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 136 | 0.030 |
Why?
|
| Blood Circulation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Operative Time | 1 | 2013 | 143 | 0.030 |
Why?
|
| Solvents | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 120 | 0.030 |
Why?
|
| Asia | 1 | 2012 | 98 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 160 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 1992 | 21 | 0.030 |
Why?
|
| Patch Tests | 1 | 1992 | 4 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 2013 | 98 | 0.030 |
Why?
|
| Tympanic Membrane | 1 | 1992 | 13 | 0.030 |
Why?
|
| Otitis Media | 1 | 1992 | 20 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 2566 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1992 | 47 | 0.030 |
Why?
|
| Risk Factors | 3 | 2013 | 5499 | 0.030 |
Why?
|
| Europe | 1 | 2012 | 321 | 0.020 |
Why?
|
| Bodily Secretions | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1992 | 107 | 0.020 |
Why?
|
| Peroxidase | 1 | 1991 | 51 | 0.020 |
Why?
|
| Dermatitis, Atopic | 1 | 2012 | 55 | 0.020 |
Why?
|
| Crying | 1 | 1991 | 6 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 275 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 339 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 11 | 0.020 |
Why?
|
| Midazolam | 1 | 1991 | 48 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1992 | 186 | 0.020 |
Why?
|
| Phenol | 1 | 1991 | 7 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 1991 | 28 | 0.020 |
Why?
|
| Models, Biological | 3 | 1995 | 1765 | 0.020 |
Why?
|
| Cedrus | 1 | 2010 | 2 | 0.020 |
Why?
|
| Picornaviridae Infections | 1 | 1990 | 7 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1991 | 36 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1991 | 26 | 0.020 |
Why?
|
| Planning Techniques | 1 | 2010 | 10 | 0.020 |
Why?
|
| Agnosia | 1 | 2010 | 5 | 0.020 |
Why?
|
| Skin | 2 | 1991 | 582 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1997 | 2486 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 385 | 0.020 |
Why?
|
| Xenon Radioisotopes | 1 | 1990 | 10 | 0.020 |
Why?
|
| Captopril | 1 | 1990 | 20 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1991 | 193 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1989 | 16 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 751 | 0.020 |
Why?
|
| In Vitro Techniques | 6 | 1990 | 996 | 0.020 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Arachidonic Acid | 2 | 1987 | 63 | 0.020 |
Why?
|
| Capillaries | 1 | 1990 | 90 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 139 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 125 | 0.020 |
Why?
|
| Neurons | 1 | 1998 | 1584 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2327 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1488 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 293 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 487 | 0.020 |
Why?
|
| Movement | 1 | 1991 | 309 | 0.020 |
Why?
|
| Calcium Channels | 1 | 1989 | 182 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2008 | 56 | 0.020 |
Why?
|
| Heart Rate | 1 | 1991 | 495 | 0.020 |
Why?
|
| Serotonin | 1 | 1989 | 221 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1988 | 24 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 330 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 18 | 0.020 |
Why?
|
| South Dakota | 1 | 2008 | 47 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3027 | 0.020 |
Why?
|
| Dopamine | 1 | 1989 | 276 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 79 | 0.020 |
Why?
|
| Body Fluids | 1 | 1988 | 34 | 0.020 |
Why?
|
| Methylhistidines | 1 | 1987 | 2 | 0.020 |
Why?
|
| Histidine Decarboxylase | 1 | 1987 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 780 | 0.020 |
Why?
|
| Carboxy-Lyases | 1 | 1987 | 22 | 0.020 |
Why?
|
| Histidine | 1 | 1987 | 56 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 231 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 202 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 114 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 216 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1988 | 207 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1987 | 5 | 0.020 |
Why?
|
| Thromboxanes | 1 | 1987 | 7 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1987 | 19 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 781 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1991 | 900 | 0.020 |
Why?
|
| Tears | 2 | 1998 | 7 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 3448 | 0.020 |
Why?
|
| Global Health | 1 | 2008 | 187 | 0.020 |
Why?
|
| Exocytosis | 1 | 1987 | 109 | 0.020 |
Why?
|
| Cost of Illness | 2 | 1997 | 147 | 0.020 |
Why?
|
| Molecular Weight | 4 | 1987 | 331 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1988 | 309 | 0.020 |
Why?
|
| Radioimmunoassay | 3 | 1992 | 155 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3385 | 0.020 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 1985 | 8 | 0.020 |
Why?
|
| Receptors, Bradykinin | 3 | 1991 | 12 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2005 | 13 | 0.020 |
Why?
|
| Lymphokines | 1 | 1985 | 76 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 1986 | 73 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 2303 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1976 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1985 | 48 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1723 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 1985 | 38 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 825 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 1595 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 56 | 0.010 |
Why?
|
| Pruritus | 1 | 2002 | 29 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 718 | 0.010 |
Why?
|
| Radiography | 1 | 1985 | 809 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 290 | 0.010 |
Why?
|
| Estrogens | 1 | 1983 | 201 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1992 | 2284 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 413 | 0.010 |
Why?
|
| Otitis Media, Suppurative | 1 | 1981 | 4 | 0.010 |
Why?
|
| Cholesteatoma | 1 | 1981 | 7 | 0.010 |
Why?
|
| Ear Canal | 1 | 1981 | 16 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1981 | 25 | 0.010 |
Why?
|
| Ear Diseases | 1 | 1981 | 20 | 0.010 |
Why?
|
| Granuloma | 1 | 1981 | 65 | 0.010 |
Why?
|
| Proteins | 2 | 1998 | 787 | 0.010 |
Why?
|
| Hearing | 1 | 1981 | 57 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1981 | 47 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 739 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1992 | 374 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1999 | 12 | 0.010 |
Why?
|
| Chromatography, Gel | 2 | 1992 | 103 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1999 | 40 | 0.010 |
Why?
|
| Substance P | 1 | 1999 | 61 | 0.010 |
Why?
|
| Cholesterol | 1 | 1981 | 359 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1990 | 31 | 0.010 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 1998 | 8 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1997 | 14 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.010 |
Why?
|
| Fever | 1 | 1998 | 128 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 4143 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1996 | 18 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 98 | 0.010 |
Why?
|
| Leukotriene E4 | 2 | 1986 | 3 | 0.010 |
Why?
|
| E-Selectin | 1 | 1994 | 30 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 73 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1994 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1994 | 25 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 1994 | 44 | 0.010 |
Why?
|
| Arthritis | 1 | 1994 | 47 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 565 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1994 | 1012 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1994 | 727 | 0.010 |
Why?
|
| Preanesthetic Medication | 1 | 1991 | 6 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 1991 | 12 | 0.010 |
Why?
|
| Anesthesia Recovery Period | 1 | 1991 | 56 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1992 | 590 | 0.010 |
Why?
|
| Capsules | 1 | 1990 | 37 | 0.010 |
Why?
|
| Ear, Middle | 1 | 1990 | 25 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1991 | 245 | 0.010 |
Why?
|
| Pressure | 1 | 1990 | 165 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1988 | 17 | 0.000 |
Why?
|
| Phytotherapy | 1 | 1989 | 136 | 0.000 |
Why?
|
| Intradermal Tests | 1 | 1987 | 3 | 0.000 |
Why?
|
| Ethmoid Sinus | 1 | 1987 | 6 | 0.000 |
Why?
|
| Endoscopes | 1 | 1987 | 9 | 0.000 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1987 | 85 | 0.000 |
Why?
|
| Colchicine | 1 | 1987 | 24 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1991 | 731 | 0.000 |
Why?
|
| Carboxypeptidases | 1 | 1987 | 35 | 0.000 |
Why?
|
| Aminopeptidases | 1 | 1987 | 17 | 0.000 |
Why?
|
| Tissue Kallikreins | 1 | 1986 | 1 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 52 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 81 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1986 | 109 | 0.000 |
Why?
|
| Physical Stimulation | 1 | 1986 | 72 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1988 | 322 | 0.000 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1985 | 4 | 0.000 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1985 | 33 | 0.000 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1985 | 39 | 0.000 |
Why?
|
| Physical Exertion | 1 | 1984 | 38 | 0.000 |
Why?
|
| Calcium | 1 | 1987 | 1175 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1985 | 805 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1981 | 2018 | 0.000 |
Why?
|